FIELD: biotechnology.
SUBSTANCE: disclosed is use of a compound containing an anti-sense oligonucleotide targeted at a nucleic acid molecule coding apolipoprotein CIII (ApoCIII) for treating or preventing progression of pancreatitis and/or chylomicronemia in an animal, to increase clearance chylomicron, fats, chylomicron triglycerides and/or triglycerides after meals, to increase level of high-density lipoprotein (HDL) and/or improving triglycerides (TG) due to decrease of TG levels and/or increasing HDL levels, by means of which is reduced risk and prevented progress of a cardiovascular disease, for decreasing levels of cholesterin ester transport protein (CEPT), to increase level of apolipoprotein A1 (AroA1) and/or paraoxonase 1 (PON1) in an animal.
EFFECT: compound containing anti-sense oligonucleotide, targeted at a nucleic acid molecule coding ApoCIII, can be used in medicine for treating and preventing cardiovascular diseases and metabolic disorders.
91 cl, 37 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODULATION OF THE EXPRESSION OF APOLIPOPROTEIN C-III (APOSIII) IN THE PATIENTS WITH LIPODYSTROPHY | 2016 |
|
RU2737719C2 |
| MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | 2014 |
|
RU2661781C2 |
| MODULATING EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2014 |
|
RU2706964C2 |
| COMPOSITIONS AND METHODS OF MODULATING APOLIPOPROTEIN C-III EXPRESSION | 2014 |
|
RU2650510C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2699985C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2824214C1 |
| ANTISENSE MODULATION OF GCGR EXPRESSION | 2012 |
|
RU2598709C2 |
| LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | 2014 |
|
RU2649367C2 |
| METHODS AND COMPOSITIONS FOR MODELING EXPRESSION OF APOLIPOPROTEIN (A) | 2013 |
|
RU2624028C2 |
| COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | 2015 |
|
RU2703411C2 |
